Development of a Cabozantinib (Cabometyx) Symptom Management Application for Use in Patients With Renal Cancer

Stopped early · Not applicable

Conditions studied: Metastatic Renal Cell Carcinoma Treated With Cabozantinib

In brief

The purpose of this study is to develop an on-line electronic symptom management application that can ultimately be used to improve clinical outcomes in patients with mRCC treated with cabozantinib.

Key facts

Study ID

NCT03867045

Run by

Duke University

People needed

1

Starts

2019-08-21

Expected to finish

2019-12-16

Last updated by the study team

2021-06-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients > 18 years of age Patients planning to start treatment with cabozantinib therapy for renal cancer.
• Technology requirement: The patient will need to have home wireless internet access for use of the software and technology in this study. The patient will need to already have or be willing to set up a Duke MyChart account.

You may not qualify if…

• Non-English Speaking. Any patient who is not able to comprehend and operate the technology at the discretion of the enrolling provider.

Where it is running

• Duke University Medical Center — Durham, North Carolina, United States
• Duke Raleigh Hospital — Raleigh, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.